Patent Application
20220143613
The present disclosure relates to collection of biomolecules.
Various biomolecules can be used as an indicator to represent a physiological state in a living body (e.g., a biomarker). In order to separate, extract, and collect biomolecules from solutions such as body fluids, there are physical methods such as centrifugation and filters, and chemical methods such as aggregation methods by reagents.
However, existing methods may not detect them in small sample volumes or at low concentrations. In addition, those methods are sometimes not practical, for example, they are costly.
The present disclosure includes a device of collecting biomolecules. A method of measuring an antigen according to an embodiment of the present disclosure may comprise.
A biomolecule may be a biological substance. A biological substance is a generic term for an organic compound of a polymer contained in a living body and functioning with respect to life phenomena, and refers to, for example, a protein, a lipid, a nucleic acid, a hormone, a sugar, an amino acid, or the like. The biomolecule may be a complex of a biomolecule, for example, a complex of a protein, and may be a multiprotein complex. The biomolecule may be a nucleic acid. The biomolecule may be a vesicle. The substance to be collected (extracted, accumulated, or the like. Hereinafter, it is also referred to as “collection”.) may not be a biomolecule or may be a non-biomolecule. The substance to be collected may be an inorganic molecule, an organic molecule, or the like.
The biomolecule may be a ribonucleic acid (RNA) or may comprise a ribonucleic acid (RNA). The RNA may be, but is not limited to, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), non-coding RNA (ncRNA), microRNA (miRNA), ribozymes, double-stranded RNA (dsRNA), or the like, and may include a plurality thereof. The RNA may be modified. RNA or miRNA may be involved in the development or progression of a cancer, a cardiovascular disease, a neurodegenerative disease, a psychiatric disease, a chronic inflammatory disease, or the like. miRNA may be a type of RNA that promotes or positively regulates canceration (onco miRNA (oncogenic miRNA, cancer-promoting miRNA)) or a type of RNA that suppresses or negatively regulates canceration (Tumor Suppressor miRNA (cancer-suppressing miRNA)). The biomolecule may be an exosome, an exosome complex.
The nucleic acid may be a deoxyribonucleic acid (DNA) or may comprise DNA.
The biomolecule may be an organelle or a vesicle. The vesicle may be, but is not limited to, a vacuole, a lysosome, a transport vesicle, a secretion, gas vesicle, an extracellular matrix vesicle, an extracellular vesicle, or the like, or may include a plurality thereof. The extracellular vesicle may be, but is not limited to, an exosome, an exotome, a shedding microvesicle, a microvesicle, a membrane particle, a plasma membrane, a poptotic vesicle, or the like. The vesicle may contain nucleic acids.
The biomolecule may be, but is not limited to, a cell and may include a cell. The cell may be a red blood cell, a white blood cell, an immune cell, or the like. The biomolecule may be a virus, a bacterium, or the like.
The solution may be a body fluid, a liquid derived from a body fluid (a diluent, a treatment liquid, or the like). The solution may be a solution that is not a body fluid (derived from a non-body fluid), may be an artificially prepared liquid, or may be a mixture of a solution derived from a body fluid or a body fluid and a solution derived from a non-body fluid. The solution may be a solution to be used for sample measurements and may be a solution to be used for measurements for calibration. The solution may be used as a stock solution, or may be a liquid in which the stock solution is diluted or concentrated. The solution may be a standard solution or a calibration solution. The sample to be measured may be a specimen. The solution may contain a physiological buffer such as phosphate buffered saline (PBS) or N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid buffer (TES), including the substance to be collected. The body fluids may include an additive. For example, a stabilizing agent or a pH adjusting agent may be added to the additive.
The “body fluid” may be a solution. The body fluid may be in a liquid state or may be in a solid state, for example, a frozen state. The solution may include a substance to be collected, such as a biomolecule, or may not include a substance to be collected, and may include a substance for measuring a substance to be collected.
The body fluid may be a body fluid of an animal. The animal may be a reptile, a mammal, an amphibian. The mammal may be a dog, cat, cow, horse, sheep, pig, hamster, mouse, squirrel, or a primate such as monkey, gorilla, chimpanzee, bonovo, human and the like.
The body fluid may be lymph fluid, tissue fluid such as interstitial fluid, intercellular fluid, interstitial fluid, and the like, or may be body cavity fluid, serosal fluid, pleural fluid, ascites fluid, capsular fluid, cerebrospinal fluid, joint fluid (synovial fluid), and aqueous humor of the eye (aqueous). The body fluid may be a digestive fluid such as saliva, gastric juice, bile, pancreatic juice, intestinal fluid, and the like, or may be sweat, tears, nasal mucus, urine, semen, vaginal fluid, amniotic fluid, milk, or the like.
“Urine” means liquid excreta produced by the kidneys. Urine may be a liquid or substance that has been excreted outward via the urethra or may be a liquid or substance that has been accumulated in the bladder. “Saliva” means a secretion that is secreted into the oral cavity from the salivary glands.
The body fluid may be extracted or accumulated/collected from the body using an extractor such as a syringe. The solution may be a body fluid of a healthy subject, may be a body fluid of a subject with a particular disease, for example but not limited to, lung cancer, liver cancer, pancreatic cancer, bladder cancer, and prostate cancer, or may be a body fluid of a subject suspected of suffering from a particular disease.
The extraction may be adsorption. The substance to be measured may be captured in a device or a fluid chamber or adsorbed on a portion of the interior thereof.
A part or all of the fluid chamber or the fluid channel such as a substrate or a spacer may be formed of an inorganic material, or may be formed of an organic material. The inorganic material forming the substrate may be, for example, a metal, silicon, or another semiconductor material, or an insulating material such as glass, ceramics, or a metal oxide.
A fluid chamber or a channel such as a substrate or a spacer may be formed of a polymer material. The polymeric material may be a natural resin, may be a synthetic resin, or may be a mixture thereof. The synthetic resin may be a thermosetting resin, may be a thermoplastic resin, or may be another resin.
The thermosetting resin may be, for example but not limited to, phenol resin (PF), epoxy resin (EP), melamine resin (MF), urea resin (urea resin, UF), unsaturated polyester resin (UP), alkyd resin, polyurethane (PUR), thermosetting polyimide (PI), or the like.
The thermoplastic resin may be, for example but not limited to, a general purpose plastic such as polyethylene (PE), high density polyethylene (HDPE), middle density polyethylene (MDPE), low density polyethylene (LDPE), polypropylene (PP), polyvinyl chloride (PVC), polyvinylidene chloride, polystyrene (PS), polyvinyl acetate (PVAc), polyurethane (PUR), Teflon-(polytetrafluoroethylene, PTFE), ABS resin (acrylonitrile butadiene styrene resin), AS resin, acrylic resin (PMMA), or the like; may be an engineering plastic such as polyamide (PA), nylon, polyacetal (POM), polycarbonate (PC), modified polyphenylene ether (m-PPE, modified PPO), polyethylene terephthalate (PET), glass fiber reinforced polyethylene terephthalate (GF minus PET), polybutylene terephthalate (PBT), cyclic polyolefin (COP) or the like; or may be a superengineering plastic such as polyphenylene sulfide (PPS), polytetrafluoroethylene (PTFE) (commonly referred to as Teflon (registered trademark)), polysulfone (PSF), polyether sulfone (PES), amorphous polyarylate (PAR), liquid crystal polymer (LCP), polyether ether ketone (PEEK), thermoplastic polyimide (PI), polyamideimide (PAI), or the like.
A part or all of the members constituting a flow channel chamber may be flat, may have a curved surface, or may have another shape (for example, bent, or the like).
In some embodiments, a flow channel chamber or flow channel (also referred to simply as a flow channel chamber in the present disclosure) may have a plurality of inner walls. The flow channel chamber or flow channel may have a space substantially surrounded by a plurality of inner walls. The flow channel chamber or flow channel may have a polygonal cross-section in part. The polygon may be, for example, triangle, rectangle, pentagon, hexagon, octagon, or the like. The plurality of inner walls may be composed of a flat inner wall, an inner wall having a curved surface, a combination thereof.
In some embodiments, the flow channel chamber or flow channel may have a member forming an inner wall inside, in addition to the inner walls forming the internal space. For example, a wall or a columnar structure may be provided in the flow channel chamber. The surfaces may constitute an inner wall. The wall or columnar structure may have a structure that protrudes or recesses from the inner wall, and may have a structure that partially traverses the internal space continuously from one inner wall to the opposing inner wall or to another inner wall.
In some embodiments, the flow channel chamber or flow channel may have a curved and continuous inner wall. For example, the flow channel chamber or the flow channel may have a shape in which a cross section of a part thereof is configured by a circle, an ellipse, or other curves.
In some embodiments, the flow channel chamber may constitute a closed space surrounded by an inner wall. The solution may be introduced through an openable and closable inlet. In some embodiments, the flow channel chamber may have an inlet and an outlet for the solution. In some embodiments, the flow channel chamber is configured as a flow channel and may be in fluid communication with other chambers or components. In some embodiments, the fluid chamber may have an air hole.
Nanowires may be disposed substantially perpendicular to the wall surface on which they are disposed. Nanowires may be disposed non-perpendicular to the wall surface where they are disposed. A plurality of nanowires may be disposed at different angles to the wall surface where they are disposed. Nanowires may be disposed parallel to the wall surface where they are disposed. The nanowires may have branched chains. The nanowires may have a single structure without branched chains or unbranched. The plurality of nanowires may include nanowires having branched chains and unbranched nanowires. The nanowires may be periodically disposed at regular intervals on the wall surface where they are disposed. The nanowires may be disposed randomly or aperiodically on the wall surface where they are placed. The nanowires may be formed by growing from a starting point on the wall surface. The nanowires may be disposed to extend from a starting point on the wall surface.
In some embodiments, the nanowires may be directly fixed to the material forming the flow channel or fluid chamber. The nanowires may be grown directly from the wall surface.
In some embodiments, the nanowires may be partially embedded in the wall surface. The nanowires may be grown starting from a growth wire embedded in the wall surface.
In some embodiments, the nanowires may be disposed throughout the wall surface. In some embodiments, the nanowires may be disposed on a part of the wall surface.
The nanowires may not be physicochemically fixed to the inner wall. For example, the nanowires or assemblies thereof may be disposed in contact with or near the inner wall. The nanowires may be macroscopically immobilized or moved by the introduction of solution. In some embodiments, the nanowires may be mechanically in contact with the inner wall, mechanically in substantial contact with the inner wall, or mechanically substantially fixed in proximity to the inner wall. For example, an aggregate of nanowires (for example, macroscopically or microscopically sheet-like aggregate) may be fixed to the inner wall using an insert, an adhesive, or the like.
In some embodiments, a surface treatment such as an activation treatment, a hydrophilic treatment, a heat treatment, a hydrothermal treatment and the like may be performed on the surface of the substrate (inner wall) or the surface of the catalyst layer on which the nanowires are formed or grown. The surface treatment may be, for example, a plasma treatment, particle (ion, radical, neutral atom, or the like) beam irradiation, light (electromagnetic wave) irradiation such as UV, EUV and the like, electron beam irradiation, mechanical treatment such as polishing, or the like. The surface treatment may be, for example, a treatment for increasing the presence of oxygen which is bonded to a metal to become Lewis acid.
As used herein, “nanowire” means a rod-like, wire-like structure having a size such as a cross-sectional shape or a diameter on the order of nanometers (for example but not limited to, a diameter of 1 to hundreds of nanometers).
The material of the nanowires may be an inorganic material or an organic material. The nanowires may be or include a metal, a non-metal, a semiconductor, a mixture or alloy thereof, or an oxide or a nitride thereof. The material of the nanowire may be or include a polymeric material. The nanowires may be wires, whiskers, fibers, and mixtures or composites thereof.
Metals used in the material of the nanowires are for example but not limited to, typical elements (alkali metal: Li, Na, K, Rb, Cs, alkaline earth metal: Ca, Sr, Ba, Ra), magnesium group elements: Be, Mg, Zn, Cd, Hg, aluminum group elements: Al, Ga, In, rare earth elements: Y, La, Ce, Pr, Nd, Sm, Eu, tin group elements: Ti, Zr, Sn, Hf, Pb, Th, iron group elements: Fe, Co, Ni, earth acid elements: V, Nb, Ta, chromium group elements: Cr, Mo, W, U, manganese group elements: Mn, Re, noble metals (copper group, coin metal): Cu, Ag, Au, platinum group elements: Ru, Rh, Pd, Os, Ir, Pt, natural radioactive elements: U and Th as a mother radioactive disintegration products: U, Th, Ra, Rn,
actinoid, transuranic elements: Np, Pu, Am, Cm, Bk, Cf, Es, Fm, Md, No, and the like, uranium or later elements, or an alloy thereof. The nanowires may be an oxide of any one of the above metals or alloys, or alloys or mixtures thereof, and may include an oxide. The material of the nanowire or at least the surface of the nanowire (for example, coating material) may be, for example but not limited to, ZnO, SiO2, Li2O, MgO, Al2O3, CaO, TiO2, Mn2O3, Fe2O3, CoO, NiO, CuO, Ga2O3, SrO, In2O3, SnO2, Sm2O3, and EuO and the like.
The nanowires may be grown by a physical vapor deposition method such as pulsed laser deposition, VLS (Vapor-Liquid-Solid) method, CVD (Chemical-Vapor-Deposition) method, arc-discharge method, laser evaporation method, organometallic vapor phase selective growth method, hydrothermal synthetic method, reactive ion etching method, baking method, or melt method.
The nanowires may be charged. The nanowires may have a charge opposite to that of the material to be collected or extracted. Thereby, as a non-limiting example, a charged biomolecule such as an extracellular vesicle, a nucleic acid, or the like can be efficiently attracted or adsorbed.
The nanowires may be fixed to the material forming the flow channel or fluid chamber via another material or member. The material between the nanowires and the wall surface material may have a catalyst for nanowire growth or may be a non-catalytic material.
The nanowires may be grown via a catalyst layer, an adhesion layer, or a growth nucleus. The “layer” may be a thin film. The “layer” may be a continuous film. The “layer” may be discontinuous. The “layer” is a continuous film, and the film may have a hole. The “layer” may be a plurality of separate thin films. The “layer” may be or include islands. The “layer” may be particles and may include particles.
The catalyst layer, adhesion layer, and growth nucleus may be a metal, an alloy, a non-metal, or a semiconductor, or an oxide, a nitride, or the like thereof, or a mixture thereof. The metal includes, but are not limited to, typical elements (alkali metal: Li, Na, K, Rb, Cs, alkaline earth metal: Ca, Sr, Ba, Ra), magnesium group elements: Be, Mg, Zn, Cd, Hg, aluminum group elements: Al, Ga, In, rare earth elements: Y, La, Ce, Pr, Nd, Sm, Eu, tin group elements: Ti, Zr, Sn, Hf, Pb, Th, iron group elements: Fe, Co, Ni, earth acid elements: V, Nb, Ta, chromium group elements: Cr, Mo, W, U, manganese group elements: Mn, Re, noble metals (copper group, coin metal): Cu, Ag, Au, platinum group elements: Ru, Rh, Pd, Os, Ir, Pt, natural radioactive elements: U and Th as a mother radioactive disintegration products: U, Th, Ra, Rn, actinoid, transuranic elements: Np, Pu, Am, Cm, Bk, Cf, Es, Fm, Md, No, and the like, uranium or later elements. The oxide may be any one of them or an oxide of an alloy.
The growth nuclei of the nanowires may be formed of a material different from the wall surface material. The growth nuclei of the nanowires may be formed of a different material than the nanowires. The growth nuclei of the nanowires may be formed of substantially the same material as the wall surface material. The growth nuclei of the nanowires may be, for example, a surface having structural irregularities. The growth nuclei of the nanowires may be, for example, a surface having chemically different properties from part to part. Mechanically, structurally or chemically different (mottled) surfaces may be more susceptible to nanowire growth nuclei in some areas than in others. For example, the irregularities may be formed by lithography and dry wet etching, and the like. For example, ions, neutral atoms, plasma, or the like may be irradiated to form a mechanically, structurally or chemically different (mottled) surface.
The length of the nanowires may be, for example but not limited to, greater than or equal to a value of 500 nm, 1 μm, 1.5 μm, 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, 9 μm, 10 μm, 11 μm, 12 μm, 13 μm, 14 μm, 15 μm, 17 μm, 20 μm, and the like. The length of the nanowires may be, for example, but not limited to, less than or equal to a value of 1 μm, 1.5 μm, 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, 9 μm, 10 μm, 11 μm, 12 μm, 13 μm, 14 μm, 15 μm, 17 μm, 20 μm, 50 μm, 100 μm, 200 μm, and the like.
The diameter of the nanowires (or size in the thickness direction) may be, for example but not limited to, greater than or equal to a value of 5 nm, 10 nm, 15 nm, 20 nm, 25 nm, 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 150 nm, 200 nm, 250 nm, 300 nm, 400 nm, 500 nm, and the like. The diameter of the nanowires (or size in the thickness direction) may be, for example but not limited to, smaller than or equal to a value of 10 nm, 15 nm, 20 nm, 25 nm, 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 150 nm, 200 nm, 250 nm, 300 nm, 400 nm, 500 nm, 1 μm, and the like.
The polymer used for the material of the nanowires may be, for example but not limited to, polymethyl methacrylate (PMMA), polystyrene (PS), polydimethylsiloxane (PDMS), conductive polymer poly(3,4-ethylenedioxythiophene)/poly(4-styrenesulfonic acid) (PEDOT/PSS), polyethylene naphthalate (PEN), polyethylene terephthalate (PET), polyimide (PI), or the like.
The nanowires may be a fibrous material and may include a fibrous material. The fibrous material may be a synthetic fiber, may be a natural fiber, and may be a mixture or mixed fibers thereof. The fibrous material may be, for example but not limited to, polyester, polypropylene, polyacrylic, polyamide, a copolymerized polyester-based fiber, polyolefin-based fibers, polyvinyl alcohol-based fiber, and the like. The fibrous material may be, for example but not limited to, a vegetable fiber such as cotton, hemp, hatch, or the like. The fibrous material used for the nanowire may be a woven fabric or a nonwoven fabric. In some embodiments, the nanowires may be a laminate of fibrous materials. In some embodiments, the nanowires may be a structure of short fibers. The length of the short fibers may be random and may have breath. The short fiber axes may be randomly arranged or regularly arranged. In some embodiments, the synthetic fibers may be a low melting point material. The low melting point material may be, for example but not limited to, a copolymerized polyester-based fiber, a polyolefin-based fiber, a polyvinyl alcohol-based fiber, or the like. In some embodiments, the synthetic fibers may have a core structure comprising a low melting point polymer.
The spacing between a pair of opposing wall surfaces having nanowires (or the size of the perpendicular direction of the plane on which the nanowires are disposed, hereinafter the same) may be twice the length of the nanowires, may be less than twice, may be 1.5 times, may be more than twice, may be 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, and may be larger than those.
The spacing between a pair of opposing wall surfaces with nanowires may be less than or equal to 10, 9, 8, 7, 6, 5, 4, 3 times the length of the nanowires.
Hereinafter, some embodiments will be described with reference to the drawings.
In some embodiments, a space may be formed within one member, for example as in
Nanowires may be formed on three or more inner wall surfaces. Nanowires may be formed on all inner wall surfaces defining the fluid chamber.
In some embodiments, it may not be possible to define the number of inner walls that constitute the internal space. In some embodiments, the internal space may be formed with a curved surface.
In some embodiments, one or more inner walls may have unevenness.
In some embodiments, the nanowires may be formed on all of the inner wall surfaces having unevenness, may not be formed on all of them, the nanowires may be formed on a part of the irregularity surface. In the fluid chamber 600 shown in
In addition to the inner walls defining the outer frame of the internal space, an uneven portion or a structure may be disposed. All of the surfaces of these uneven portions and structures and the inner walls defining the outer frame of the internal space may be referred to as inner walls. The surfaces of the inner walls defining the outer frame of the internal space, the surfaces of the uneven portion and the structure may be defined as other inner walls.
Nanowires may be formed on all of the surfaces of these uneven portions and structures and the inner walls defining the outer frame of the internal space or nanowires may be formed on a part thereof. Nanowires may be formed on all the surfaces of the inner walls, or nanowires may be formed on a part or all of the surface.
In some embodiments, the unevenness or structures disposed in the internal space may be so-called chaotic mixers and may have a structure that causes non-linear and/or three-dimensional flow of the fluid flowing through the internal space. Such a structure may have, for example, a change in step or cross-sectional area in the flow channel, such as a change in the direction of the flow channel.
The structure for providing a step, or a structure that gives variation in the cross-sectional area, and the change in the direction of the flow channel may be provided on one inner wall, or may be provided on at least one inner wall or a plurality of the inner walls.
The uneven structure or a structure body such as chaotic mixer may take on a variety of configurations. For example, a concave portion may be formed in the inner wall. The concave portion may be formed in a stripe shape (groove). The concave portion may be formed as a plurality of parallel stripes. The stripe-shaped concave portions may be parallel to or angled with respect to the direction in which the solution flows. The angle may be substantially vertical or may be between 0 and 90 degrees.
The uneven structure or a structure body such as chaotic mixer may be linear or bent.
A chaotic mixer having unevenness in a herringbone shape on an inner wall surface of a flow channel can promote nonlinear flow of a fluid. Thus, by way of example, nanowires disposed on a plurality of inner wall surfaces or curved inner wall surfaces can trap more biomolecules in the solution.
Structures such as walls and pillars disposed on the inner wall surface of the flow channel may be formed continuously to the opposing inner walls, or may not be continuous to the opposing walls and may have an end in the internal space. These structures are capable of agitating the flowing solution. Thus, by way of example, nanowires disposed on a plurality of inner wall surfaces or curved inner wall surfaces can trap more biomolecules in the solution.
The flow channel may be straight, bent, or curved.
In some embodiments, the fluid chamber or flow channel device may be connected to or configured to be connected to an analysis device. In some embodiments, the fluid chamber or flow channel device may be incorporated in an analysis device. The analysis device may be, for example but not limited to, an analytical or measuring device, such as optical, magnetic, electrical, chemical, electrochemical, or the like. In some embodiments, the analysis device may be a measurement nucleic acid (RNA, DNA) sequencer. In some embodiments, it may be a microarray.
The present disclosure includes a method of collecting, extracting or accumulating biomolecules (also simply referred to as a collection method). In some embodiments, the collection method may include introducing a solution into a fluid chamber or flow channel (hereinafter also referred to as a fluid chamber) or bringing the solution into contact with the nanowires.
In some embodiments, the introduction of a solution into a fluid device may cause the solution to rest substantially in the fluid device after introducing the solution. In some embodiments, the introduction of a solution into the fluid device may continue to flow the solution continuously into the fluid device. For example, it may be continued to introduce a solution from an inlet of a flow channel device and discharge the solution that has passed through the fluid channel device from the outlet. For example, the solution may be in contact with the nanowires while constantly flowing in the fluid device.
In collecting charged molecules such as microRNAs, the nanowires may have a positive surface charge. For example, the nanowires may be contacted with body fluids under pH conditions where the nanowires have a positive surface charge. This allows, for example, free and EV inclusive forms of microRNA to be captured on the nanowires. In some embodiments, the pH of the body fluid may be adjusted such that the nanowires have a positive surface charge. In some embodiments, the nanowires may be made of a material or method having a positive surface charge to match the pH of the solution.
In some embodiments, the collection method may include adjusting the pH of the solution. The pH of the solution may be adjusted before, after, or during contact with the nanowires. In some embodiments, the pH of the body fluid may be adjusted to be greater than or equal to a value such as 2, 3, 4, or 5. In some embodiments, the pH of the body fluid may be adjusted to be less than or equal to a value such as 10, 9, 8, 7, 6, or 5. In some embodiments, the pH of urine may be adjusted to 6 to 8.
In some embodiments, in the collection, a dissociating agent (or a releaser, a dissociating solution, a solution for dissociating, or the like) may be introduced after introduction of the solution into the fluid device. This allows, for example, molecules captured by the nanowire or in the fluid device to dissociate from the nanowires. In some embodiments, the collection method may include collecting supplemental material along with the dissociating agent. The dissociating agent may include a buffering agent. In some embodiments, the dissociating agent may comprise a surfactant. The surfactant may be, for example, a nonionic surfactant and may be an ionic surfactant. This allows, for example, the RNA contained in the EV captured by the nanowires or the RNA in free form in solution and captured by the nanowires to dissociate from the nanowire. In some embodiments, the dissociating agent may include a RNase inhibitor.
In some embodiments, the collection method may include washing after introduction of the solution into the fluid device. In some embodiments, the collection method may perform washing prior to introduction of the releaser. Washing may include introducing water, a buffer, a washing liquid, or the like (simply referred to as a washing liquid) into a fluid device. The washing may cause the washing liquid after the washing to be discharged. Thus, substances other than the substance captured by the nanowires (solution or molecules) can be discharged out of the fluid device, for example but in a non-reducing manner In some embodiments, washing may not be performed. For example, it may be non-washed.
The present disclosure also includes methods of measuring and analyzing collected molecules. In some embodiments, biomolecules collected in a fluid device may be analyzed. In some embodiments, the amount of expression of RNA in a body fluid may be analyzed. The RNA may be microRNA. In some embodiments, the expression profile of RNA collected in a fluidic device may be measured using a microarray or sequencer. The measurement may include introducing a solution containing the collected RNA into a microarray or sequencer.
The present disclosure also includes diagnostic methods. In some embodiments, the diagnosis of a disease, the risk of a disease, or the like may be performed on the basis of the expression profile of the RNA collected in a fluid device, the amount of expression of one or more specific RNAs, or temporal changes thereof.
The present disclosure includes a program or software for performing a measurement method, an analysis method, and a diagnostic method. The program or the software may be recorded in a storage medium. The method may include transmitting the expression profile of RNA collected in the fluid device, or the amount of expression of one or more specific RNAs, to a computing device, such as a PC, server, CPU, and the like. It may include receiving the expression profile of the RNA collected in a fluidic device, or the amount of expression of one or more specific RNAs. Receiving and transmitting may be performed by wire, wirelessly, or transmitted via the Internet. Saving, storage, and transmission and reception of data may be performed via a cloud. Analysis and diagnosis may be performed using artificial intelligence, machine learning, depth learning, or the like.
The disclosure also includes the following embodiments:
A biomolecule collection device, comprising:
A biomolecule collection device, comprising:
A biomolecule collection device, comprising:
The biomolecule collection device according to embodiment A02,
wherein the fluid chamber comprises:
The biomolecule collection device according to embodiment A02, wherein the fluid chamber comprises:
The biomolecule collection device according to any one of embodiments A01 to A04, wherein at least one of the plurality of inner walls has a uneven structure.
The biomolecule collection device according to any one of embodiments A01 to A11, wherein the fluid chamber has an inlet for introducing a solution containing a biomolecule, and an outlet for discharging it, the fluid chamber being configured as a flow channel in which the solution flows.
The biomolecule collection device according to any one of embodiments A1 to A21, wherein the fluid chamber includes a chaotic mixer.
The biomolecule collection device according to any one of embodiment A22, wherein the nanowires are disposed on at least a portion of a surface of the chaotic mixer.
A biomolecule collection device according to any one of embodiments A1 to A23, wherein the nanowires are disposed directly on a surface on which the nanowires are disposed.
A biomolecule collection device according to any one of embodiments A1 to A31, wherein the nanowires are embedded at one end thereof in an inner wall on which the nanowires are disposed.
A biomolecule collection device according to any one of embodiments A1 to A31, wherein the nanowires are embedded at one end thereof in an inner wall on which the nanowires are disposed.
A biomolecule collection device according to any one of embodiments A1 to A31, wherein the inner wall on which the nanowires are disposed has a growth layer, and wherein the nanowires are formed by growing on the growth layer.
The biomolecule collection device according to embodiment A33, wherein the growth layer includes a catalyst for growing the nanowires.
A biomolecule analysis device comprising said biomolecule device.
A method for collecting biomolecules, comprising
A method for collecting biomolecules according to embodiment C01,
wherein said introducing the solution including the biomolecule into the biomolecule collection device is continuously introducing the solution including the biomolecule.
The method according to embodiment C01 or C02, further comprising
The method according to any one of embodiments C01 to C03,
wherein the biomolecule includes microRNA.
The method according to embodiment C04,
wherein the solution is urine or saliva.
A method of analyzing RNA expression, comprising:
The method according to embodiment D01,
wherein said estimating the amount of expression of the RNA in the body fluid includes determining an expression profile of the RNA in the body fluid.
The method of embodiment D01 or D02,
wherein the body fluid is urine or saliva.
While several embodiments and examples of the present disclosure have been described above, these embodiments and examples illustratively explain the present disclosure. For example, each of the embodiments described above has been described in detail in order to explain the present disclosure in an easy-to-understand manner, and dimensions, configurations, materials, and circuits may be additionally changed as necessary. Embodiments in which one or more features of the present disclosure described above are arbitrarily combined are also included in the scope of the present disclosure. It is intended that the appended claims cover numerous modifications to the embodiments without departing from the spirit and scope of the present disclosure. Accordingly, the embodiments and examples disclosed herein have been shown by way of illustration and should not be considered as limiting the scope of the present disclosure.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2019-014906 | Jan 2019 | JP | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/JP2020/003284 | 1/29/2020 | WO | 00 |
